| The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases. | The Roles of c-Jun N-Terminal Kinase (JNK) in Infectious Diseases.
Chen J, Ye C, Wan C, Li G, Peng L, Peng Y, Fang R., Free PMC Article | 10/30/2021 |
| Identification and neuroprotective evaluation of a potential c-Jun N-terminal kinase 3 inhibitor through structure-based virtual screening and in-vitro assay. | Identification and neuroprotective evaluation of a potential c-Jun N-terminal kinase 3 inhibitor through structure-based virtual screening and in-vitro assay.
Rajan RK, Ramanathan M. | 08/21/2021 |
| MicroRNA-4516-mediated regulation of MAPK10 relies on 3' UTR cis-acting variants and contributes to the altered risk of Hirschsprung disease. | MicroRNA-4516-mediated regulation of MAPK10 relies on 3' UTR cis-acting variants and contributes to the altered risk of Hirschsprung disease.
Wang Y, Jiang Q, Chakravarti A, Cai H, Xu Z, Wu W, Gu B, Li L, Cai W., Free PMC Article | 07/10/2021 |
| JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases. | JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases.
Musi CA, Agrò G, Santarella F, Iervasi E, Borsello T., Free PMC Article | 06/19/2021 |
| Genetic variants in MAPK10 modify renal cell carcinoma susceptibility and clinical outcomes. | Genetic variants in MAPK10 modify renal cell carcinoma susceptibility and clinical outcomes.
Tsai YC, Huang CY, Hsueh YM, Fan YC, Fong YC, Huang SP, Geng JH, Chen LC, Lu TL, Bao BY. | 05/8/2021 |
| Circ_0000515 drives the progression of hepatocellular carcinoma by regulating MAPK10. | Circ_0000515 drives the progression of hepatocellular carcinoma by regulating MAPK10.
Li H, Li CM, Yuan R, Wang HB, Wei J. | 04/24/2021 |
| Propofol suppresses the progression of nonsmall cell lung cancer via downregulation of the miR215p/MAPK10 axis. | Propofol suppresses the progression of non‑small cell lung cancer via downregulation of the miR‑21‑5p/MAPK10 axis.
Wu X, Li X, Xu G., Free PMC Article | 03/13/2021 |
| Structural mechanisms of the arrestin-3/JNK3 interactions have been reported. | Structural Mechanism of the Arrestin-3/JNK3 Interaction.
Park JY, Qu CX, Li RR, Yang F, Yu X, Tian ZM, Shen YM, Cai BY, Yun Y, Sun JP, Chung KY. | 05/2/2020 |
| the present study identified a novel significant association between the increased expression levels of MAPK10, TUBB2B and RASL11B, and neuroblastoma cells. | Upregulation of MAPK10, TUBB2B and RASL11B may contribute to the development of neuroblastoma.
Liu J, Li Y., Free PMC Article | 02/8/2020 |
| phosphorylation rate of JNK3 at Thr-221 by MKK7 is two orders of magnitude faster than the corresponding phosphorylation of Tyr-223 by MKK4 with or without arrestin-3 | Arrestin-3 scaffolding of the JNK3 cascade suggests a mechanism for signal amplification.
Perry NA, Kaoud TS, Ortega OO, Kaya AI, Marcus DJ, Pleinis JM, Berndt S, Chen Q, Zhan X, Dalby KN, Lopez CF, Iverson TM, Gurevich VV., Free PMC Article | 03/16/2019 |
| Mapk10 expression was regulated by miR27a-3p in nasopharyngeal carcinoma.Mapk10 gene was down-regulated in the nasopharyngeal carcinoma cells. | Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10.
Li L, Luo Z., Free PMC Article | 06/24/2017 |
| Peptide mini-scaffold facilitates JNK3 activation in cells. | Peptide mini-scaffold facilitates JNK3 activation in cells.
Zhan X, Stoy H, Kaoud TS, Perry NA, Chen Q, Perez A, Els-Heindl S, Slagis JV, Iverson TM, Beck-Sickinger AG, Gurevich EV, Dalby KN, Gurevich VV., Free PMC Article | 12/31/2016 |
| Study found that JNK3 levels are increased in brain tissue and CSF from patients with Alzheimer disease and CSF levels could reflect the rate of cognitive decline | Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline.
Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F, Laplanche JL, Meurs EF, Mouton-Liger F, Hugon J., Free PMC Article | 10/17/2015 |
| Data indicate that tetra-substituted pyridinylimidazoles were designed as dual inhibitors of c-Jun N-terminal kinase (JNK) 3 and p38alpha mitogen-activated protein (MAP) kinase, and both kinases may be involved in the progression of Huntington's disease. | Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA. | 05/2/2015 |
| JNK3 is required for the antiapoptotic effects of exendin 4 | JNK3 is required for the cytoprotective effect of exendin 4.
Ezanno H, Pawlowski V, Abdelli S, Boutry R, Gmyr V, Kerr-Conte J, Bonny C, Pattou F, Abderrahmani A., Free PMC Article | 02/28/2015 |
| analysis of the unique mechanisms by which JNK1beta1 is regulated | Phosphorylation- and nucleotide-binding-induced changes to the stability and hydrogen exchange patterns of JNK1β1 provide insight into its mechanisms of activation.
Owen GR, Stoychev S, Achilonu I, Dirr HW. | 02/7/2015 |
| Mitogen-activated protein kinase 10 JNK3 alpha (JNK3apha2)binds to both domains of arrestin-3. | Arrestin-3 binds the MAP kinase JNK3α2 via multiple sites on both domains.
Zhan X, Perez A, Gimenez LE, Vishnivetskiy SA, Gurevich VV., Free PMC Article | 09/27/2014 |
| miR-29b mRNA, MAPK10 protein expression, and ATG9A protein expression are closely related to chemosensitivity of ovarian carcinoma. | Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma.
Dai F, Zhang Y, Chen Y. | 08/9/2014 |
| Subtle structural mechanisms for allosteric signaling between the peptide-binding site and activation loop of human JNK3. | Structural mechanisms of allostery and autoinhibition in JNK family kinases.
Laughlin JD, Nwachukwu JC, Figuera-Losada M, Cherry L, Nettles KW, LoGrasso PV., Free PMC Article | 05/18/2013 |
| reduced JNK3 activity has potentially deleterious effects on neuronal function via altered regulation of a set of post-synaptic proteins. | Characterisation of de novo MAPK10/JNK3 truncation mutations associated with cognitive disorders in two unrelated patients.
Kunde SA, Rademacher N, Tzschach A, Wiedersberg E, Ullmann R, Kalscheuer VM, Shoichet SA. | 05/4/2013 |
| Silent scaffolds: inhibition OF c-Jun N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant. | Silent scaffolds: inhibition OF c-Jun N-terminal kinase 3 activity in cell by dominant-negative arrestin-3 mutant.
Breitman M, Kook S, Gimenez LE, Lizama BN, Palazzo MC, Gurevich EV, Gurevich VV., Free PMC Article | 08/25/2012 |
| [review] This review focuses on delineating the role of scaffold proteins, especially that of JNK3 as a target, on the regulation of JNK signaling in neurons. | JNK3 as a therapeutic target for neurodegenerative diseases.
Antoniou X, Falconi M, Di Marino D, Borsello T. | 02/11/2012 |
| Arrestin-3 acts as a "true" scaffold, facilitating JNK3alpha2 phosphorylation by bringing it and MAP kinase kinase (MKK)4 together. | Nonvisual arrestins function as simple scaffolds assembling the MKK4-JNK3α2 signaling complex.
Zhan X, Kaoud TS, Dalby KN, Gurevich VV., Free PMC Article | 01/28/2012 |
| The results suggest the possible involvement of CaMKII and JNK3 in soman-induced long-term neurotoxicity. | Regional alterations of JNK3 and CaMKIIα subunit expression in the rat brain after soman poisoning.
Ramarao G, Waghmare C, Srivastava N, Bhattacharya B. | 09/10/2011 |
| results suggest that MAPK10 may have a proapoptotic function and could function as a tumor-suppressor gene in chromophobe renal cell carcinoma | Identification of MAPK10 as a novel epigenetic marker for chromophobe kidney cancer.
Yoo KH, Park YK, Kim HS, Jung WW, Chang SG. | 06/25/2011 |